In adults with severe hypertriglyceridemia
(sHTG; TGs ≥500 mg/dL)1
Help get your patients out of the danger zone
The first and only FDA-approved therapy to reduce triglycerides and the risk of acute pancreatitis in adults with sHTG, as an adjunct to diet.1
TG=triglyceride.
The efficacy and safety of TRYNGOLZA 50 mg and 80 mg were evaluated in 2 randomized, double-blind, placebo-controlled, phase 3 clinical trials (CORE and CORE2), which included 1061 adults with sHTG (triglyceride levels ≥500 mg/dL). The primary endpoint was mean percent change in fasting triglycerides from baseline to Month 6* compared with placebo.1,2
Robust TG reduction
Up to 72% statistically significant mean change in fasting triglycerides with TRYNGOLZA 80 mg at Month 6* compared with placebo.1†
†TRYNGOLZA 50 mg and 80 mg demonstrated a significant mean change of -63% and -72% in CORE and -49% and -55% in CORE2, respectively, in fasting triglycerides from baseline to Month 6 compared with placebo (P<0.0001; primary endpoint).1
Substantial AP reduction
Up to 91% reduction in the adjudicated acute pancreatitis event rate with TRYNGOLZA 50 mg compared with placebo.1‡§
‡In the integrated analysis of CORE and CORE2, TRYNGOLZA 50 mg and 80 mg demonstrated reductions of 91% (RR: 0.09; 95% CI: 0.02, 0.42) and 76% (RR: 0.24; 95% CI: 0.08, 0.69), respectively, in adjudicated acute pancreatitis event rates over 53 weeks compared with placebo. The pooled TRYNGOLZA group demonstrated an 85% reduction (RR: 0.15; 95% CI: 0.05, 0.40).1
Proven safety profile
5% of TRYNGOLZA-treated patients discontinued due to adverse reactions vs 2% of placebo-treated patients.1
The most common adverse reactions (incidence ≥2% higher than placebo) were injection-site reactions and liver enzyme increases.1
Flexible, once-monthly dosing
A monthly SC injection, self-administered via a convenient autoinjector.1,3
Get your patients started
TRYNGOLZA is available through a select pharmacy network.
*Average of Weeks 25 and 27.1
§Pancreatitis events were assessed as a secondary endpoint in an integrated analysis of CORE and CORE2. Events were adjudicated by a blinded, independent committee according to the Revised Atlanta Diagnostic Criteria. Time to first event was compared between pooled TRYNGOLZA (50 mg and 80 mg) and pooled placebo using a log-rank test stratified by trial. Event rates over 53 weeks were compared between pooled TRYNGOLZA (50 mg and 80 mg) and pooled placebo using a negative binomial regression model.1
AP=acute pancreatitis; RR=rate ratio; SC=subcutaneous.